Brief: Aligos Therapeutics Announces U.S. FDA Clearance Of Ind Application For Alg-000184
22/10/2024 13:15
Oct 22 (Reuters) - Aligos Therapeutics Inc ALGS.O :
* ALIGOS THERAPEUTICS ANNOUNCES U.S. FDA CLEARANCE OF IND
APPLICATION FOR ALG-000184
* ALIGOS THERAPEUTICS INC - PHASE 2 FILING FOR ALG-000184
PLANNED
FOR Q1 2025
Source text for Eikon: ID:nGNX3PFtyt
Further company coverage: ALGS.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue